Engineered T Cells Market Statistics - 2030
The global engineered T cells market was valued at $9,668.0 million in 2020, and is projected to reach $149,650.6 million by 2030, registering a CAGR of 32.5% from 2021 to 2030. The growth of the global engineered T cells market is majorly driven by increase in prevalence of different types of cancers such as lung cancer, blood cancer, and brain tumor. For instance, as per the report of Globocan 2020, published by world health organization (WHO), lung cancer is the second ranked cancer in terms of patient count in Europe with estimated 477,534 newly diagnosed patients. Moreover, advantages of genetically engineered t cells therapies over traditional cancer treatments such as chemotherapy are expected to fuel their adoption in the analysis period.
Engineered T cells are specifically altered T cells designed for the treatment of cancer. Currently, these cells are being used for therapeutic and research purposes, which include tumor infiltrating lymphocytes, T cell receptor (TCR), and chimeric antigen receptor (CAR). Moreover, engineered T cells are used to treat various cancers and overcome immune suppressive tumor microenvironments, where T cells are not capable of detecting tumor cells as a foreign object. Furthermore, they are the engineered T cells that aim to reduce toxicities and restrict antigen escape (inability of immune system to respond to an infectious agent) for effective therapeutic actions.
Get more information on this report :
Surge in government initiatives to treat chronic diseases drives the growth of market. Globally, governments of all regions have increased their expenditure on the healthcare sector. For instance, by 2020, the U.S. Government spent about 4.1 trillion, or 19.7% of GDP on healthcare expenditures. It has been estimated that approximately 30% of the healthcare expenditure is used in upgrading infrastructure, especially medical equipment used at public health centers (hospitals).
Furthermore, increase in geriatric population contributes in growth of market. The old age people are more susceptible to the chronic diseases such as hypertension, diabetes, and cancers.
For instance, according to National Cancer Institute’s report published on March 2021, the incidence rates for cancer overall climbs steadily as age increases, from fewer than 25 cases per 100,000 people in age groups under age 20, to about 350 per 100,000 people among those aged 45 to 49, to more than 1,000 per 100,000 people in age groups 60 years and older.
In addition, advancement in T cell therapy and new product launches by key manufacturer are anticipated to contribute toward the growth of the market. For instance, in May 2020, Lilly, a leading manufacturer of pharmaceuticals, received U.S. Food and Drug Administration (FDA) approval for ‘Cyramza(ramucirumab injection, 10 mg/mL solution)’ in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer. However, high cost of treatments and potential risk of engineered T cell treatments impede the growth of this market.
Engineered T Cells Market Segmentation
The engineered T cells market is segmented on the basis of type, application, end user, and region. By type, the market is mainly categorized into chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes
By application, it is categorized into lung cancer, breast cancer, colorectal cancer, melanoma, leukemia and others application.Based on end user, it is divided into, hospital, cancer research center, and clinic
By Product
Chimeric Antigen Receptor (Car) Modified T Cells segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By region, the market is analyzed across North America (U.S.,Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain,and Rest of Europe), Asia-Pacific (Japan, China, Australia, India,South Korea, Taiwan,and Rest of Asia-Pacific), and LAMEA(Brazil, Turkey, South Arabia, South Africa, and LAMEA).
Segment Review
Depending on type, the chimeric antigen receptor (CAR) modified t cells segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to rise in awareness about CAR-T cell therapies and recent product approval of CAR-T cell treatment by the FDA. However, the T cells receptor (TCR) modified T cells segment is expected to witness considerable growth during the forecast period due to advancement in T cell therapy.
By Application
Lung Cancer was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Based on application, the lung cancer segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to surge in lung cancer patients and increase in sedentary lifestyle such as smoking and alcohol consumption. However, the breast cancer segment is expected to witness considerable growth during the forecast period due to increase in diagnosis of breast cancer, rise in prevalence of breast cancer, and advancement in R&D activities for therapeutic treatment of breast cancer by key players.
Depending on end user, the hospitals segment was the major contributor in 2020 and is expected to maintain its lead during the forecast period, owing to rise in number of cancer hospitals, and initiatives taken by government & private organization for development of hospital infrastructure. However, the cancer research centers segment is expected to witness considerable growth during the forecast period due to increase in number of cancer research centers and advancement in technology in healthcare sector
By End User
Hospitals was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Depending on the region, North America garnered the major share in the engineered T cells market in 2020, and is expected to dominate the global market during the forecast period, owing to the rise in prevalence of cancer, presence of key players for development of T cell therapy, and well-established infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 33.6% from 2021 to 2030, owing to an increase in the number of hospitals, prevalence of cancer, and high population.
The key players that operate in the global engineered T cells market include Amgen Inc, AthenexInc, Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly And Company, Gilead Sciences, Inc., Novartis AG, Oxford BiomedicaPlc, Pfizer Inc., and Precision Biosciences Inc.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Benefits For Stakeholders
- The report provides an in-depth analysis of the global engineered T cells market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis of the region assists to understand the regional market and facilitate strategic business planning & determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global engineered T cells market growth.
Engineered T Cells Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Byapplication |
|
 By Byend user |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
Engineered T cells are mainly used for the treatment of cancer and diabetes. The chimeric antigen receptor (CAR) modified T cells, T cells receptor (TCR) modified T cells, and tumor infiltrating lymphocytes are the most common type of engineered T cells. Chimeric antigen receptor (CAR) modified T cells dominate the market owing to increase in R&D activity in car T cell therapy.
Factors such as increase in prevalence of cancer, rise in number of hospitals, and surge in geriatric population drive the growth of the market. In addition, advancement in T cell technologies in healthcare sector are expected to drive the growth of the engineered T cells market.
North America is expected to witness the highest growth, in terms of revenue, owing to the rise in prevalence of cancer, the presence of key players for R&D in T cell therapy, and increase in number of cancer hospitals & diagnostic centers in the region.
However, the high cost of treatments and potential risk of engineered T cell treatments are expected to hamper market growth during the forecast period.
The total market value of engineered T cells market is $9668 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of engineered T cells market in 2021 was $11862.7 million
The base year for the report is 2020.
Yes, engineered T cells companies are profiled in the report
The top companies that hold the market share in engineered T cells market are Amgen Inc, Athenex Inc, Bellicum Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly And Company, Gilead Sciences, Inc., Novartis Ag, Oxford Biomedica Plc, Pfizer Inc., and Precision Biosciences Inc.
Asia-Pacific is expected to register the highest CAGR of 33.6% from 2021 to 2030, owing to increase in number of hospitals, and advancement in engineered T cell.
The key trends in the engineered T cells market are by an increase in the prevalence of cancer; rise in number of hospitals; and R&D in engineered T cells.
Loading Table Of Content...
